Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Thavorncharoensap M1, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P 1Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Thailand ; Heal

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. Inthira Yamabhai; Richard D. Smith Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T

A cost–utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Adun Mohara1, Román Pérez Velasco1, Naiyana Praditsitthikorn1,2, Yingyos Avihingsanon3 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP),

Abstract BACKGROUND: Recently, the second-generation tyrosine kinase inhibitors dasatinib and nilotinib have emerged as alternative treatments in patients with chronic myeloid leukemia (CML) who are resistant to or intolerant of imatinib. OBJECTIVE: This article aimed to assess the cos

Abstract (provisional) Background Over the last decade, the prevalence of obesity (BMI >= 25 kg/m2) in Thailand has been rising rapidly and consistently. Estimating the cost of obesity to society is an essential step in setting priorities for research and resource use and helping improve pu

Rapeepong Suphanchaimat1,2 Angkana Sommanustweechai1 , Chiraporn Khitdee1 , Chompoonut Thaichinda1 , Kanang Kantamaturapoj3 , Pattara Leelahavarong4 , Pensom Jumriangrit1 , Thitikorn Topothai1 , Thunthita Wisaijohn1 Weerasak Putthasri1 1International Health Policy Program (IHPP), Ministry of Publi

Abstract Objectives In Thailand, axillary lymph node dissection (ALND) is the dominant form of treatment for breast cancer, even though the treatment often leaves patients with some degree of arm morbidity. Sentinel lymph node biopsy (SNB) is widely accepted globally as a preferable alternative pr

Abstract Background: Breast cancer risk prediction models are widely used in clinical practice. They should be useful in identifying high risk women for screening in limited-resource countries. However, previous models showed poor performance in derived and validated settings. Therefore, we aimed